Results 91 to 100 of about 43,721 (231)

UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Autism Spectrum Disorder

Neuropsychopharmacology Reports, Volume 46, Issue 3, September 2026.
A case series studying outcomes up to 18 months in autistic patients from the UK Medical Cannabis Registry. ABSTRACT Introduction Autism spectrum disorder (ASD) is a neurodevelopmental disorder associated with distressed behaviors and psychological challenges.
Arushika Aggarwal, Simon Erridge, Madhur Varadpande, Evonne Clarke, Katy McLachlan, Ross Coomber, Muhammed Asghar, Urmila Bhoskar, Matthieu Crews, Andrea De Angelis, Muhammad Imran, Fariha Kamal, Laura Korb, Gracia Mwimba, Simmi Sachdeva‐Mohan, Gabriel Shaya, James J. Rucker, Mikael H. Sodergren   +17 more
wiley   +1 more source

Psychiatric effects of cannabidiol, cannabinol, and tetrahydrocannabinol: A narrative review of clinical evidence and risk profiles

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 3, September 2026.
Abstract Cannabinoid products are increasingly used worldwide despite limited psychiatric evidence. This narrative review synthesizes preclinical and clinical evidence on cannabidiol (CBD), cannabinol (CBN), and tetrahydrocannabinol (THC) to clarify their distinct psychiatric profiles and discuss how current evidence may inform ongoing clinical and ...
Yasuhiro Kishi, Ichiro Takumi, Kakusho Chigusa Nakajima‐Ohyama   +2 more
wiley   +1 more source

CB1 and CB2 Receptor Expression in Type 1 Diabetic Neuropathic Rats Is Enhanced by Photobiomodulation Therapy

Photonics
Background: The interaction between the endocannabinoid system (ECS), specifically the CB1 and CB2 cannabinoid receptors, and neuropathy has aroused great research interest due to the possible implications for treatment.
Danielle Paula Freitas Bataus Silva, Natalia Vendrame, Willians Fernando Vieira, Marucia Chacur   +3 more
doaj   +1 more source

Positioning Incretin‐Based and Next‐Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta‐Analyses

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7768-7778, September 2026.
ABSTRACT Background The obesity pharmacotherapy landscape is evolving rapidly, with several approved incretin‐based therapies and an expanding pipeline of investigational compounds targeting multiple metabolic pathways. Conventional evidence syntheses often struggle to accommodate differences in dose selection, treatment duration and stage of clinical ...
Matteo Monami, Benedetta Ragghianti, Edoardo Mannucci   +2 more
wiley   +1 more source

Structural insights into cannabinoid receptors CB1 and CB2: determinants of ligand selectivity

Frontiers in Chemical Biology
Cannabinoid receptors 1 (CB1) and 2 (CB2) are key components of the endocannabinoid system and play central roles in regulating diverse physiological processes, including neural signaling, immune modulation, and inflammation. Both receptors belong to the
Ann Varghese, Jie Liu, Wenjing Guo, Tucker A. Patterson, Huixiao Hong   +4 more
doaj   +1 more source

The Cannabinoid Receptor CB1 Modulates the Signaling Properties of the Lysophosphatidylinositol Receptor GPR55*

Journal of Biological Chemistry, 2012
Background: G protein-coupled receptors (GPCR) can form heteromers and thereby alter their signaling properties. Results: GPR55 and cannabinoid 1 (CB1) receptor signaling is modulated if receptors are co-expressed.
J. Kargl, Nariman Balenga, G. Parzmair, Andrew J. Brown, A. Heinemann, M. Waldhoer   +5 more
semanticscholar   +1 more source

mGluR5 in ECCCK to BLA Circuit Modulates Depressive‐Like Phenotypes through CCK Signaling

Advanced Science, Volume 13, Issue 43, 3 August 2026.
Dysregulation of mGluR5 and CCK signaling contributes to major depressive disorder, yet circuit‐level mechanisms remain unclear. Here, the ECCCK→BLA pathway is identified as a critical regulator of affective behavior. mGluR5 modulates synaptic function and CCK signaling within this circuit, controlling stress susceptibility and depressive‐like states ...
Muhammad Asim, Huajie Wang, Gao Qianqian, Abdul Waris, Jufang He   +4 more
wiley   +1 more source

Toxicological properties of Δ9-tetrahydrocannabinol and cannabidiol

Arhiv za Higijenu Rada i Toksikologiju, 2020
Cannabis sativa L. contains more than 100 phytocannabinoids that can interact with cannabinoid receptors CB1 and CB2. None of the cannabinoid receptor ligands is entirely CB1- or CB2-specific. The effects of cannabinoids therefore differ not just because
Černe Katarina
doaj   +1 more source

In Vitro Metabolism of Δ8‐, Δ9‐, and Δ10‐THC in Human Hepatocytes: Distinct Δ10‐THC Biotransformation and Implications for Drug Testing

Drug Testing and Analysis, Volume 18, Issue 8, Page 1114-1121, August 2026.
Δ8‐THC and Δ9‐THC showed comparable metabolic profiles. In contrast, Δ10‐THC underwent extensive glucuronidation and hydroxylation, with only minor formation of a carboxy metabolite, indicating a markedly different metabolic pathway. These differences may increase the risk of misidentification and misinterpretation in cannabis drug testing.
Robert Kronstrand, Henrik Green, Markus Loh, Fabian Rüttimann, Manuela Carla Monti   +4 more
wiley   +1 more source

Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Augments cAMP Accumulation in Striatal Neurons: Evidence for a Gs Linkage to the CB1 Receptor

Journal of Neuroscience, 1997
Cannabinoids act at the CB1 receptor to inhibit adenylate cyclase activity via a pertussis toxin-sensitive G-protein. Within the striatum, CB1 receptors have been shown to be localized on the same neurons as Gi-coupled dopamine D2 receptors.
M. Glass, C. Felder
semanticscholar   +1 more source